ETFIQData as of Nov 12, 2026. · etfiq.com/funds/kure

KURE Fact Sheet: KraneShares MSCI All China Health Care Index ETF

Share
$18.30
close, Nov 12, 2026

Over the year to Nov 12, 2026, KURE returned −1.9% in total and charged 0.65% a year.

1-year total return
−1.9%
to Nov 12, 2026
Expense ratio
0.65%
a year
Net assets
$114m
on Nov 11, 2026

Growth of $10,000, 1 year

KURE $9,814 −1.9% · Total return, distributions reinvested, Nov 12, 2025 to Nov 12, 2026.

Returns

WindowTotal return
1 month+1.2%
3 months−1.9%
Year to date+7.4%
1 year−1.9%
3 years+4.8%
5 years−35.8%

Total return, distributions reinvested, each window to Nov 12, 2026.

Ten largest positions

HoldingWeight
BEONE MEDICINES LTD9.64%
INNOVENT BIOLOGICS INC8.14%
WUXI BIOLOGICS CAYMAN INC7.56%
WUXI APPTEC CO LTD-A5.54%
JIANGSU HENGRUI PHARMACEUT-A4.48%
SHENZHEN MINDRAY BIO-MEDIC-A4.30%
AKESO INC4.15%
SINO BIOPHARMACEUTICAL3.91%
CSPC PHARMACEUTICAL GROUP LT3.47%
WUXI APPTEC CO LTD-H3.19%

KURE top ten by weight, 54.4% of the fund, of its 50 equity positions, from the holdings published by its issuer for Nov 11, 2026.

Facts

Equity fund · Tracks an index · First traded Feb 1, 2018 · Benchmark Its own holdings, as of Nov 11, 2026

Source: ETFIQ, from issuer disclosures, SEC filings and exchange prices. Returns from daily closes, distributions reinvested; each number is dated beside it, and every one is on the fund’s page.Cite as: ETFIQ, KURE Fact Sheet: KraneShares MSCI All China Health Care Index ETF. Data as of Nov 12, 2026. https://etfiq.com/funds/kure/fact-sheet/ETFIQ is an independent publisher. Not an issuer, broker or adviser. No recommendations. Printed from etfiq.com/funds/kure.